Observational study of hand-foot syndrome events from XELOX therapy for metastatic colorectal cancer. - The study of metastatic colorectal cancer to investigate impact of learning effect.

Fujita Health University0 个研究点目标入组 100 人开始时间: 2012年2月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Pleural effusion, peritoneal fluid and pericardial fluid. 2. Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ. 3. Serious drug hypersensitivity or a history of drug allergy for Fluorouracil, leucovorin calcium or platinum agents. 4. Dihydropyrimidine Dehydrogenase Deficiency. 5. Evidence of interstinal lung disease, or pulmonary fibrosis. 6. Uncontrolled Active infection. 7. Difficulty on oral intake. 8. Other conditions not suitable for this study 9. Symptomatic brain metastasis. 10. Complication of cerebrovascular disease or symptoms within 1 year. 11. Any surgical treatments including skin open biopsy, trauma surgery and other more intensive surgery within 4 weeks or aspiration biopsy within one week. 12. Planned surgery during this study. 13. Administering antithrombotic drug within 10 days. 14. Need to administrate or having anti-platelets therapy (including Methotrexate aspirin and NSAIDs). 15. Evidence of bleeding diathesis or coagulopathy. 16. Active gastrointestinal ulcer. 17. Renal failure to be treated, 2+ or higher proteinuria within 2 weeks prior to entry. 18. Uncontrolled Hypertension. 19. Clinically significant (i.e. active) cardiovascular disease, or past or current history (within the last 1 year) of myocardial infarction

发起方